Eikon Therapeutics, Inc. (EIKN) Revenue, Earnings & Financial Statements
$5.15NASDAQ: EIKNMarket Cap $278.81M
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Eikon Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $324.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Income Statement — 1 Years (USD millions)
Metric
2025
Revenue
$0
Operating Expenses
$339.0M
Operating Profit
−$339.0M
Other Income
$15.0M
Interest
$1.0M
Depreciation
$24.0M
Profit Before Tax
−$324.0M
Tax rate (%)
0.0%
Net Profit
−$324.0M
EPS
−$6.16
Quarterly Results — Last 5 Quarters (USD millions)
Metric
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
$0
Operating Expenses
$75.0M
$83.0M
$87.0M
$93.0M
$91.0M
Operating Profit
−$75.0M
−$83.0M
−$87.0M
−$93.0M
−$91.0M
Interest
$0
$0
$0
$0
$4.0M
Profit Before Tax
−$71.0M
−$80.0M
−$83.0M
−$88.0M
−$86.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$71.0M
−$80.0M
−$83.0M
−$88.0M
−$86.0M
EPS
$0.00
−$1.47
−$1.53
−$1.63
−$1.59
Balance Sheet — 1 Years (USD millions)
Metric
2025
Total Assets
$595.0M
Current Assets
$349.0M
Cash
$105.0M
Inventory
$0
Receivables
$0
Fixed Assets
$234.0M
Capital Work in Progress
$0
Investments
$231.0M
Other Assets
$0
Total Liabilities
$1.5B
Current Liabilities
$55.0M
Borrowings
$257.0M
Other Liabilities
$1.2B
Equity
$0
Reserves
−$879.0M
Cash Flow Statement — 1 Years (USD millions)
Metric
2025
Operating Cash Flow
−$189.0M
Investing Cash Flow
−$228.0M
Financing Cash Flow
$0
Net Cash Flow
−$18.0M
Free Cash Flow
−$235.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.01
EV / EBITDA
-1.58
FCF Yield
-71.78%
Quick Ratio
9.89
Interest Coverage
-339.00
Return 1Y
—
Return 3Y
—
Return 5Y
—
Eikon Therapeutics, Inc. (EIKN) financials — frequently asked questions
What is Eikon Therapeutics, Inc.'s annual revenue?
Eikon Therapeutics, Inc. (EIKN) reported annual revenue of $0 in its most recent fiscal year.
What is Eikon Therapeutics, Inc.'s net profit?
Eikon Therapeutics, Inc. (EIKN) reported a net loss of $324.0M in its most recent fiscal year.
What is EIKN EV/EBITDA?
Eikon Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -1.58. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks